Arbutus Biopharma (ABUS) Intangibles (2015 - 2019)

Arbutus Biopharma has disclosed Intangibles across 5 years of filings, most recently posting $43.8 million for Q2 2019.

• Intangibles for Q2 2019 came in at $43.8 million, down 25.25% year-over-year; the trailing twelve-month figure through Jun 2019 was $43.8 million (down 25.25% YoY), and the FY2018 annual result was $43.8 million, down 25.25% from the prior year.
• Intangibles came in at $43.8 million for Q2 2019 at Arbutus Biopharma, roughly flat from $43.8 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $390.0 million in Q2 2015 to a low of $43.8 million in Q3 2018.
• The 5-year median for Intangibles is $99.4 million (2016), against an average of $165.6 million.
• Peak annual rise in Intangibles reached 9.5% in 2016, while the deepest fall reached 71.8% in 2016.
• Arbutus Biopharma's Intangibles stood at $352.6 million in 2015, then tumbled by 71.8% to $99.4 million in 2016, then tumbled by 41.03% to $58.6 million in 2017, then declined by 25.25% to $43.8 million in 2018, then changed by 0.0% to $43.8 million in 2019.
• The last three Intangibles figures came in at $43.8 million (Q2 2019), $43.8 million (Q1 2019), and $43.8 million (Q4 2018), per Business Quant data.